Preferred Label : Peroxisome biogenesis disorder 3a (zellweger);
Symbol : PBD3A;
CISMeF acronym : CG3; PBD3A;
Type : Phenotype, molecular basis known;
Included titles and symbols : Peroxisome biogenesis disorder, complementation group 3; CG3;
Description : The peroxisomal biogenesis disorder (PBD) Zellweger syndrome (ZS) is an autosomal
recessive multiple congenital anomaly syndrome resulting from disordered peroxisome
biogenesis. Affected children present in the newborn period with profound hypotonia,
seizures, and inability to feed. Characteristic craniofacial anomalies, eye abnormalities,
neuronal migration defects, hepatomegaly, and chondrodysplasia punctata are present.
Children with this condition do not show any significant development and usually die
in the first year of life (summary by Steinberg et al., 2006). For a complete phenotypic
description and a discussion of genetic heterogeneity of Zellweger syndrome, see 214100.
Individuals with PBDs of complementation group 3 (CG3) have mutations in the PEX12
gene. For information on the history of PBD complementation groups, see 214100.;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutation in the peroxisome biogenesis factor 12 gene (PEX12, 601758.0001);
Laboratory abnormalities : Pipecolic acid elevated in urine and serum; Increased very long chain fatty acids (VLCFAs); Zellweger complementation group 3; Reduced plasmalogens; Normal serum phytanic acid; No peroxisomal matrix protein import in fibroblasts; Normal serum pristanic acid;
Prefixed ID : #614859;
Origin ID : 614859;
UMLS CUI : C3553929;
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)